Drug Safety Communication: Initial safety trial results find increased risk of serious heart-related problems and cancer with Xeljanz, Xeljanz XR (tofacitinib)

Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?